BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30299237)

  • 1. Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors.
    Tirosh A; Journy N; Folio LR; Lee C; Leite C; Yao J; Kovacs W; Linehan WM; Malayeri A; Kebebew E; Berrington de González A
    Radiology; 2019 Jan; 290(1):116-124. PubMed ID: 30299237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential value of EUS in pancreatic surveillance of VHL patients.
    van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Koopmans KP; Kema IP; Zonnenberg BA; Timmers HJ; de Herder WW; Sluiter WJ; de Vries EG; Links TP
    Eur J Endocrinol; 2016 May; 174(5):611-20. PubMed ID: 26884551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
    Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E
    J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison.
    Marcos HB; Libutti SK; Alexander HR; Lubensky IA; Bartlett DL; Walther MM; Linehan WM; Glenn GM; Choyke PL
    Radiology; 2002 Dec; 225(3):751-8. PubMed ID: 12461257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
    de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
    Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.
    Krauss T; Ferrara AM; Links TP; Wellner U; Bancos I; Kvachenyuk A; Villar Gómez de Las Heras K; Yukina MY; Petrov R; Bullivant G; von Duecker L; Jadhav S; Ploeckinger U; Welin S; Schalin-Jäntti C; Gimm O; Pfeifer M; Ngeow J; Hasse-Lazar K; Sansó G; Qi X; Ugurlu MU; Diaz RE; Wohllk N; Peczkowska M; Aberle J; Lourenço DM; Pereira MAA; Fragoso MCBV; Hoff AO; Almeida MQ; Violante AHD; Quidute ARP; Zhang Z; Recasens M; Díaz LR; Kunavisarut T; Wannachalee T; Sirinvaravong S; Jonasch E; Grozinsky-Glasberg S; Fraenkel M; Beltsevich D; Egorov VI; Bausch D; Schott M; Tiling N; Pennelli G; Zschiedrich S; Därr R; Ruf J; Denecke T; Link KH; Zovato S; von Dobschuetz E; Yaremchuk S; Amthauer H; Makay Ö; Patocs A; Walz MK; Huber TB; Seufert J; Hellman P; Kim RH; Kuchinskaya E; Schiavi F; Malinoc A; Reisch N; Jarzab B; Barontini M; Januszewicz A; Shah N; Young WF; Opocher G; Eng C; Neumann HPH; Bausch B
    Endocr Relat Cancer; 2018 Sep; 25(9):783-793. PubMed ID: 29748190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of pancreatic involvement in von Hippel-Lindau disease: a retrospective study of 55 cases in a single center.
    Park TY; Lee SK; Park JS; Oh D; Song TJ; Park DH; Lee SS; Seo DW; Kim MH
    Scand J Gastroenterol; 2015 Mar; 50(3):360-7. PubMed ID: 25562111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings.
    Hough DM; Stephens DH; Johnson CD; Binkovitz LA
    AJR Am J Roentgenol; 1994 May; 162(5):1091-4. PubMed ID: 8165988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome.
    Penitenti F; Landoni L; Scardoni M; Piredda ML; Cingarlini S; Scarpa A; D'Onofrio M; Girelli D; Davi MV
    Endocrine; 2021 Oct; 74(1):180-187. PubMed ID: 34036514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome.
    Weisbrod AB; Kitano M; Thomas F; Williams D; Gulati N; Gesuwan K; Liu Y; Venzon D; Turkbey I; Choyke P; Yao J; Libutti SK; Nilubol N; Linehan WM; Kebebew E
    J Am Coll Surg; 2014 Feb; 218(2):163-9. PubMed ID: 24440063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic manifestations of von Hippel-Lindau disease-effect of imaging on clinical management.
    Davenport MS; Caoili EM; Cohan RH; Hoff CN; Ellis JH
    J Comput Assist Tomogr; 2010 Jul; 34(4):517-22. PubMed ID: 20657218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome.
    Weisbrod AB; Liewehr DJ; Steinberg SM; Patterson EE; Libutti SK; Linehan WM; Nilubol N; Kebebew E
    Ann Surg Oncol; 2012 Jun; 19(6):2054-9. PubMed ID: 22350603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gastroenterological manifestations of von Hippel-Lindau disease - a case report].
    Koniusz J; Dąbkowski K; Buczek K; Gomółka A; Starzyńska T
    Pol Merkur Lekarski; 2017 Aug; 43(254):66-68. PubMed ID: 28875972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).
    Blansfield JA; Choyke L; Morita SY; Choyke PL; Pingpank JF; Alexander HR; Seidel G; Shutack Y; Yuldasheva N; Eugeni M; Bartlett DL; Glenn GM; Middelton L; Linehan WM; Libutti SK
    Surgery; 2007 Dec; 142(6):814-8; discussion 818.e1-2. PubMed ID: 18063061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
    Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
    Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease.
    Tamura K; Nishimori I; Ito T; Yamasaki I; Igarashi H; Shuin T
    World J Gastroenterol; 2010 Sep; 16(36):4515-8. PubMed ID: 20857520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Pancreatic Neuroendocrine Tumor on Mortality in Patients With von Hippel-Lindau Disease.
    Arnon L; Halperin R; Tirosh A
    Endocr Pract; 2021 Oct; 27(10):1040-1045. PubMed ID: 33737209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
    Kitano M; Millo C; Rahbari R; Herscovitch P; Gesuwan K; Webb RC; Venkatesan AM; Phan GQ; Hughes MS; Libutti SK; Nilubol N; Linehan WM; Kebebew E
    Surgery; 2011 Dec; 150(6):1122-8. PubMed ID: 22136831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.